PL3468577T3 - Koniugaty białka prionowego z dendrymerami do zastosowania w leczeniu choroby alzheimera - Google Patents

Koniugaty białka prionowego z dendrymerami do zastosowania w leczeniu choroby alzheimera

Info

Publication number
PL3468577T3
PL3468577T3 PL17728263T PL17728263T PL3468577T3 PL 3468577 T3 PL3468577 T3 PL 3468577T3 PL 17728263 T PL17728263 T PL 17728263T PL 17728263 T PL17728263 T PL 17728263T PL 3468577 T3 PL3468577 T3 PL 3468577T3
Authority
PL
Poland
Prior art keywords
dendrimers
alzheimer
disease
treatment
prion protein
Prior art date
Application number
PL17728263T
Other languages
English (en)
Inventor
Krzysztof NIEZNAŃSKI
Hanna NIEZNAŃSKA
Witold K. SUREWICZ
Krystyna SUREWICZ
Magdalena BANDYSZEWSKA
Original Assignee
Instytut Biologii Doświadczalnej Im. Marcelego Nenckiego Polskiej Akademii Nauk
Case Western Reserve University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Biologii Doświadczalnej Im. Marcelego Nenckiego Polskiej Akademii Nauk, Case Western Reserve University filed Critical Instytut Biologii Doświadczalnej Im. Marcelego Nenckiego Polskiej Akademii Nauk
Publication of PL3468577T3 publication Critical patent/PL3468577T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PL17728263T 2016-05-11 2017-05-10 Koniugaty białka prionowego z dendrymerami do zastosowania w leczeniu choroby alzheimera PL3468577T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL417159A PL417159A1 (pl) 2016-05-11 2016-05-11 Koniugaty białka prionowego z dendrymerami do zastosowania w leczeniu choroby Alzheimera
EP17728263.9A EP3468577B1 (en) 2016-05-11 2017-05-10 Prion protein-dendrimer conjugates for use in treatment of alzheimer disease
PCT/IB2017/052733 WO2017195131A1 (en) 2016-05-11 2017-05-10 Prion protein-dendrimer conjugates for use in treatment of alzheimer disease

Publications (1)

Publication Number Publication Date
PL3468577T3 true PL3468577T3 (pl) 2022-02-14

Family

ID=59014670

Family Applications (2)

Application Number Title Priority Date Filing Date
PL417159A PL417159A1 (pl) 2016-05-11 2016-05-11 Koniugaty białka prionowego z dendrymerami do zastosowania w leczeniu choroby Alzheimera
PL17728263T PL3468577T3 (pl) 2016-05-11 2017-05-10 Koniugaty białka prionowego z dendrymerami do zastosowania w leczeniu choroby alzheimera

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL417159A PL417159A1 (pl) 2016-05-11 2016-05-11 Koniugaty białka prionowego z dendrymerami do zastosowania w leczeniu choroby Alzheimera

Country Status (6)

Country Link
US (1) US10815292B2 (pl)
EP (1) EP3468577B1 (pl)
ES (1) ES2901053T3 (pl)
IL (1) IL262902B2 (pl)
PL (2) PL417159A1 (pl)
WO (1) WO2017195131A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112439074B (zh) * 2020-12-03 2022-09-13 浙江大学 可快速提高功能多肽亲和力的偶联物及其制备方法和应用
CN115737787B (zh) * 2022-12-15 2024-04-19 四川大学 乳铁蛋白联合胆碱在制备预防和/或治疗阿尔兹海默症的药物中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE277640T1 (de) 1994-03-07 2004-10-15 Dow Chemical Co Bioaktive und/oder gezielte dendrimere-konjugate enthaltend genetisches material
KR19990029749A (ko) 1997-09-17 1999-04-26 미우라 아끼라 2가 반응성 수용성 고분자 유도체 및 이들을 함유하는 복합체
WO2002042462A2 (en) 2000-11-27 2002-05-30 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
US7217845B2 (en) 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives
US20050267029A1 (en) * 2004-04-02 2005-12-01 Ancsin John B Compounds which modulate amyloidogenesis and methods for their identification and use
CN101160403B (zh) 2005-02-18 2014-08-13 安吉奥开米公司 转运化合物穿过血脑屏障的分子
CA2719878C (en) * 2007-04-26 2017-08-29 Yale University Prion protein as a receptor for amyloid-beta oligomers
WO2009041902A1 (en) 2007-09-25 2009-04-02 Loefgren Kajsa Prion protein derived cell penetrating peptides and their uses
WO2014026283A1 (en) * 2012-08-14 2014-02-20 Angiochem Inc. Peptide-dendrimer conjugates and uses thereof

Also Published As

Publication number Publication date
WO2017195131A1 (en) 2017-11-16
US20190092837A1 (en) 2019-03-28
ES2901053T3 (es) 2022-03-21
PL417159A1 (pl) 2017-11-20
IL262902B2 (en) 2023-02-01
US10815292B2 (en) 2020-10-27
IL262902A (en) 2019-03-31
EP3468577B1 (en) 2021-09-15
EP3468577A1 (en) 2019-04-17
IL262902B (en) 2022-10-01

Similar Documents

Publication Publication Date Title
IL285722A (en) Methods for treating alzheimer's disease
SA519410311B1 (ar) أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
HUE053239T2 (hu) Humanizált tau-ellenanyagok Alzheimer-kór kezelésére
MX2018008557A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos.
HUE056006T2 (hu) Kombináció Parkinson-kór kezelésére
LT3416631T (lt) Terapiniai agentai, skirti neurodegeneracinių ligų gydymui
IL263433A (en) Methods for treating alzheimer's disease
SI3720433T1 (sl) Bis-holin tetratiomolibdat za zdravljenje Wilsonove bolezni
EP3437540A4 (en) ENDOSKOP HOLDER
DK2994160T3 (da) Behandling af alzheimers sygdom subpopulationer med poolet immunoglobulin g
HUE054783T2 (hu) Pridopidin Huntington-kór kezelésében
EP3501312A4 (en) WOMEN'S UNDERWEAR
EP3605180A4 (en) IMAGING LENS
EP4663754A3 (en) BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE
DK3463351T3 (da) Behandling til parkinsons sygdom
HUE063369T2 (hu) Vegyületek Alzheimer-kór kezelésében történõ alkalmazásra APOE4+/+ betegekben
PL3347002T3 (pl) Leczenie choroby alzheimera w konkretnej populacji pacjentów
CY1127309T1 (el) Ebselen για χρηση στη θεραπεια της νοσου meniep
IL256000A (en) Quantifying her 2 protein for optimal cancer therapy
EP3482698A4 (en) HEMOSTATIC INSTRUMENT
EP3414517A4 (en) HOLOGRAFIC CHARACTERIZATION OF PROTEIN UNITS
HUE062806T2 (hu) Vektorok Friedreich-ataxia kezelésére
LT3413870T (lt) Igmesinas, skirtas panaudoti alzheimerio ligos gydymui
IL262902A (en) Prion protein-dendrimer conjugates for use in treatment of alzheimer disease
IL254252A0 (en) History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease